Hybridoma cell line secreting famoxadone monoclonal antibody and use thereof
By developing the oxazomedone monoclonal antibody hybridoma cell line, the complex sample preprocessing and long detection time of the oxazomedone residue detection method are solved, and efficient and rapid oxazomedone residue detection is achieved, providing High specificity and high sensitivity detection methods are suitable for food safety testing.
Patent Information
- Application Number
- PCT/CN2024/087166
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-04-11
- Publication Date
- 2024-11-21
AI Technical Summary
The existing oxazomedone pesticide residue detection methods have the problems of complex sample preprocessing and long detection time, which is difficult to apply to the rapid detection of large numbers of samples. It lacks monoclonal antibodies with high specificity and high sensitivity, which limits enzyme-linked immunity. Application of method.
A hybridoma cell line secreting monoclonal antibody of oxazomedone was developed to prepare a complete antigen by coupling oxazomedone hapten with carrier proteins for enzyme-linked immunoassay detection, providing high specificity and high sensitivity Antibodies are used to establish rapid detection methods for oxazomedone residues.
It realizes efficient and rapid detection of oxazomedone, with an IC50 value of 1.31ng/mL, which is suitable for food safety testing, reduces the detection cost and sample pretreatment complexity, and is suitable for on-site rapid detection of large numbers of samples.
Smart Images

Figure CN2024087166_21112024_PF_FP_ABST
Abstract
Description
A hybridoma cell line secreting famoxadone monoclonal antibody and its application Technical Field
[0001] The invention belongs to the technical field of immune detection, and in particular relates to a hybridoma cell line secreting famoxadone monoclonal antibody and application thereof. Background Art
[0002] Oxamfedaconazole is a new protective fungicide that primarily blocks the ubiquinolase enzyme, inhibiting the release of pathogenic spores and achieving a fungicidal effect. It is used to control various downy mildews, black spot, and late blight. Oxamfedaconazole has been introduced in my country for pest and disease control of crops, particularly potatoes, grapes, and cereals. However, improper use can lead to excessive residues in crops, potentially harming consumer health. Therefore, it is necessary to develop an efficient and rapid detection method for oxamfedaconazole residues.
[0003] High-performance liquid chromatography, gas chromatography, and gas or liquid chromatography-mass spectrometry are commonly used to detect famoxadone pesticide residues. However, these methods suffer from complex sample pretreatment and long detection times, making them unsuitable for rapid testing of large numbers of samples. To protect the interests of consumers, it is necessary to develop a simple, rapid, and sensitive method for the detection of famoxadone.
[0004] Enzyme-linked immunosorbent assay (ELISA) is an extremely efficient, sensitive, and rapid detection method. It requires minimal sample pretreatment, requires minimal purification steps, has a large analytical capacity, is low-cost, and is easy to use. It is suitable for rapid on-site testing of large numbers of samples, and therefore has been widely used in pesticide residue analysis. However, the detection of famoxadone using ELISA requires the development of a highly specific and sensitive monoclonal antibody against famoxadone. Therefore, developing a method for preparing such a highly specific and sensitive monoclonal antibody is crucial.
[0005] Summary of the Invention
[0006] In order to solve the above technical problems, the present invention provides a hybridoma cell line that secretes a monoclonal antibody against famoxadone. The monoclonal antibody against famoxadone secreted by the hybridoma cell line has good specificity and detection sensitivity (IC 50 The value is 1.31 ng / mL), which can be used to establish an immunological detection method for famoxadone and detect the residues of famoxadone in food.
[0007] The first object of the present invention is to provide a hybridoma cell line that secretes a monoclonal antibody against famoxadone, wherein the hybridoma cell line was deposited in the General Microbiology Center of the China Culture Collection Administration on February 8, 2023, with a deposit number of CGMCC No.45462.
[0008] Furthermore, the hybridoma cell line was obtained by immunizing an animal with a complete antigen prepared from the famoxadone hapten shown in the following structure:
[0009] Furthermore, the complete antigen is obtained by coupling the famoxadone hapten with a carrier protein.
[0010] Furthermore, the carrier protein includes but is not limited to bovine serum albumin BSA, ovalbumin OVA, keyhole limpet hemocyanin KLH, etc.
[0011] The second object of the present invention is to provide the use of the hybridoma cell line secreting famoxadone monoclonal antibodies in the detection of famoxadone.
[0012] The third object of the present invention is to provide a famoxadone monoclonal antibody, which is secreted by the above hybridoma cell line.
[0013] The fourth object of the present invention is to provide the use of the above-mentioned famoxadone monoclonal antibody in the detection of famoxadone.
[0014] A fifth object of the present invention is to provide a famoxadone detection product, wherein the famoxadone detection product comprises the above-mentioned famoxadone monoclonal antibody. Of course, the detection product can be prepared into any form such as a kit, a reagent, or a test strip.
[0015] Furthermore, the above-mentioned famoxadone detection product can be used for the residual analysis and detection of famoxadone in food safety testing.
[0016] Furthermore, the famoxadone detection product also includes famoxadone coating agent.
[0017] Furthermore, the famoxadone coating is obtained by activating the famoxadone hapten and coupling it with chicken ovalbumin.
[0018] The above technical solution of the present invention has the following advantages over the prior art:
[0019] The present invention provides a monoclonal antibody hybridoma cell line with high affinity, good specificity and detection sensitivity to oxathiapiprolin. The IC value of the monoclonal antibody to oxathiapiprolin is 50 The concentration of the test substance is 1.31 ng / mL, and the cross-reaction rate to oxathiapiprolin analogs is less than 1%. It can be used to establish an enzyme-linked immunosorbent assay method for oxathiapiprolin, laying the foundation for the research, development and promotion of indirect competitive ELISA kits and colloidal gold test strips, helping to realize the detection of oxathiapiprolin residues, and providing immunoassay methods and raw materials for the immunoassay of oxathiapiprolin residues in food, which has practical application value.
[0020] Biomaterial Deposit
[0021] Monoclonal cell line SFA, the monoclonal cell line SFA was deposited in the General Microbiology Center of China Culture Collection Administration on February 8, 2023, with the deposit number CGMCC No. 45462, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below based on specific embodiments of the present invention in conjunction with the accompanying drawings, wherein
[0023] FIG1 is a standard inhibition curve of the famoxadone monoclonal antibody of the present invention against famoxadone. DETAILED DESCRIPTION
[0024] The present invention will be further described below with reference to the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it. However, the embodiments are not intended to limit the present invention.
[0025] The culture medium involved in the following examples is as follows:
[0026] RPMI-1640 medium (mg / L): L-arginine 290, L-asparagine 50, L-aspartic acid 20, L-cystine dihydrochloride 65.15, L-glutamic acid 20, glycine 10, L-histidine 15, L-hydroxyproline 20, L-isoleucine 50, L-leucine 50, L-lysine hydrochloride 40, L-methionine 15, L-phenylalanine 15, L-proline 20, L-serine 30, L-threonine 20, L-tryptophan 5, L-Tyrosine 23.19, L-Valine 20, p-Aminobenzoic acid 1, Calcium nitrate 100, Anhydrous magnesium sulfate 48.84, Anhydrous sodium dihydrogen phosphate 676.13, Potassium chloride 400, Sodium chloride 6000, Glucose 2000, Reduced glutathione 1, Phenol red 5, L-Glutamine 300, Biotin 0.2, D-Calcium pantothenate 0.25, Folic acid 1, i-Inositol 35, Nicotinamide 1, Choline chloride 3, Pyridoxine hydrochloride 1, Riboflavin 0.2, Thiamine hydrochloride 1, Vitamin B12 0.005, Sodium bicarbonate 2000.
[0027] The reagents involved in the following examples are as follows:
[0028] Carbonate buffer (CBS): Weigh 1.59 g of Na2CO3 and 2.93 g of NaHCO3, dissolve them in a small amount of double-distilled water, mix them, add double-distilled water to about 800 mL, adjust the pH to 9.6, add double-distilled water to 1000 mL, and store at 4°C until used;
[0029] Phosphate buffered saline (PBS): 8.00 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, 2.9 g Na2HPO4·12H2O, dissolved in 800 mL pure water, adjusted to pH 7.2–7.4 with NaOH or HCl, and made up to 1000 mL.
[0030] PBST: PBS containing 0.05% Tween 20;
[0031] Antibody diluent: PBS supplemented with 0.1% gelatin.
[0032] TMB colorimetric solution: Solution A: 18.43 g Na₂HPO₄·12H₂O, 9.33 g citric acid, dilute to 1000 mL with purified water; Solution B: 60 mg TMB dissolved in 100 mL ethylene glycol. Mix Solution A and Solution B in a 5:1 volume ratio to create the TMB colorimetric solution. Mix immediately before use.
[0033] The detection methods involved in the following embodiments are as follows:
[0034] Method for detecting the inhibition rate of oxathiapiprolin: The most appropriate antigen and antibody concentrations for IC-ELISA were selected by a checkerboard test. The antigen was diluted to 0.03, 0.1, 0.3, and 1 μg / mL with carbonate buffer (CBS), and the antibody was diluted to 0.03, 0.1, 0.3, and 1 μg / mL with antibody diluent. After selecting the optimal working point, the oxathiapiprolin standard was diluted to concentrations of 0, 0.03, 0.1, 0.3, 0.9, 2.7, 8.1, and 24.3 ng / mL. The IC-ELISA procedure was followed, and finally, OriginPro 8.5 was used to create a graph to obtain the oxathiapiprolin standard inhibition curve and calculate the IC 50 .
[0035] Example 1 Synthesis of famoxadone hapten
[0036] Since the small molecule of oxathiapiprolin is not immunogenic and cannot stimulate mice to produce an immune response and then produce antibodies, it is necessary to couple oxathiapiprolin to the protein through protein coupling technology to make it immunogenic; the active groups commonly used in protein coupling technology include amino, carboxyl, hydroxyl, thiol, etc. Since the molecular structure of oxathiapiprolin does not contain amino, carboxyl, or hydroxyl groups, it is necessary to derive a carboxyl group from its structure.
[0037] The structure of the hapten of the derivatized famoxadone of the present invention is as follows:
[0038] The derivation process includes the following:
[0039] Dissolve 100 mg of famoxadone in 5 mL of pyridine in an Erlenmeyer flask. Add 112 mg of succinic anhydride and react in a 70°C water bath with magnetic stirring for 4 hours. Drain the reaction mixture with nitrogen. Dissolve the precipitate in 2 mL of chloroform and extract three times with equal volumes of ultrapure water. Collect the organic phase and drain under nitrogen. The precipitate is the derivative product.
[0040] Example 2 Synthesis of complete famoxadone antigen
[0041] The complete famoxadone antigen, abbreviated as FAM-COOH-BSA, has the following molecular formula:
[0042] 6.5 mg of famoxadone hapten (FAM-COOH) and 4.2 mg of N-hydroxysuccinimide (NHS) were weighed and dissolved in 300 μL of N,N-dimethylformamide (DMF) and stirred at room temperature for 10 minutes. 5.8 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was then weighed and fully dissolved in 100 μL of DMF. The mixture was then added to the FAM-COOH solution and stirred at room temperature for 4-6 hours (referred to as Solution A). 6 mg of BSA was diluted to 2 mg / mL in 0.01 M carbonate buffer (CBS) (referred to as Solution B). Solution A was then slowly added dropwise to Solution B and allowed to react at room temperature overnight. The solution was then dialyzed against 0.01 M PBS to remove unreacted small molecule hapten, yielding the complete antigen, FAM-COOH-BSA, which was then identified by UV absorption scanning.
[0043] Example 3 Synthesis of Oxamethylenetetracycline Coating
[0044] 5.6 mg of famoxadone hapten (FPF-COOH) and 3.4 mg of N-hydroxysuccinimide (NHS) were dissolved in 300 μL of anhydrous N,N-dimethylformamide (DMF) and stirred at room temperature for 10 minutes to obtain a famoxadone hapten (FAM-COOH) solution. 4.6 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was dissolved in 100 μL of anhydrous DMF and added to the FAM-COOH solution. The mixture was stirred at room temperature for 4-6 hours to obtain solution A. 6 mg of chicken ovalbumin (OVA) was diluted with 3 mL of 0.01 M carbonate buffer (CBS) to obtain solution B. Solution A was slowly added dropwise to solution B to react and obtain a reaction solution. The reaction solution was dialyzed with PBS solution to remove unreacted small molecule hapten to obtain the coating source (FAM-COOH-OVA).
[0045] Example 4 Preparation of Hybridoma Cell Lines Secreting Monoclonal Antibodies to Famoxadone
[0046] 1. Immunization of Animals: After emulsification, complete famoxadone antigen was mixed with an equal amount of Freund's adjuvant and injected subcutaneously at multiple points in the back of the neck of BALB / c mice (except for booster immunization). Complete Freund's adjuvant was used for the first immunization at a dose of 100 μg per mouse. Incomplete Freund's adjuvant was used for multiple booster immunizations, and the dose was halved to 50 μg per mouse. No adjuvant was used for the booster immunization, which was directly diluted with normal saline and injected intraperitoneally, and the dose was further halved to 25 μg per mouse. The interval between the first and second booster immunizations was one month, between multiple booster immunizations was 21 days, and between the booster immunization and the final booster immunization was 18-21 days. The immune response of mice was assessed by indirect competitive enzyme-linked immunosorbent assay (IC-ELISA), i.e., the titer and inhibition of mouse serum were measured.
[0047] 2. Cell fusion: Three days after the sprint immunization, cell fusion was performed according to the conventional PEG (polyethylene glycol, molecular weight 4000) method. The specific steps are as follows:
[0048] a. Blood was collected by tail amputation. Mice were sacrificed by cervical dislocation and immediately disinfected in 75% alcohol for about 5 minutes. The spleen of the mouse was removed aseptically. The spleen was moderately ground with the rubber tip of a syringe and passed through a 200-mesh cell sieve to obtain a splenocyte suspension. The suspension was collected and centrifuged (1200 rpm, 8 minutes). The splenocytes were washed three times with RPMI-1640 medium. After the final centrifugation, the splenocytes were diluted to a certain volume, counted, and set aside.
[0049] b. Collection of SP2 / 0 cells: 7-10 days before fusion, SP2 / 0 tumor cells were cultured in RPMI-1640 medium containing 10% FBS (fetal bovine serum) in a 5% CO2 incubator. Before fusion, the number of SP2 / 0 tumor cells should reach (1-4) × 10 7 , ensure that SP2 / 0 tumor cells are in the logarithmic growth phase before fusion. When fusion occurs, tumor cells are collected, suspended in RPMI-1640 basal culture medium, and cell counts are performed;
[0050] c. Fusion process 7 min: In the first minute, 1 mL of PEG 1500 was added dropwise to the cells from slow to fast addition; in the second minute, the cells were allowed to stand; in the third and fourth minutes, 1 mL of RPMI-1640 medium was added dropwise over 1 min; in the fifth and sixth minutes, 2 mL of RPMI-1640 medium was added dropwise over 1 min; in the seventh minute, 1 mL of RPMI-1640 medium was added dropwise every 10 s; the cells were then incubated at 37°C for 5 min; centrifuged (800 rpm, 8 min), the supernatant was discarded, and the cells were resuspended in RPMI-1640 screening medium containing 20% fetal bovine serum and 2% 50× HAT, and 200 μL / well were added to a 96-well cell plate and cultured in a 37°C, 5% CO2 incubator.
[0051] 3. Cell screening and cell line establishment: On the third day after cell fusion, the fused cells were subjected to a half-change of RPMI-1640 screening medium. On the fifth day, the medium was fully changed with RPMI-1640 transition medium containing 20% fetal bovine serum and 1% 100×HT. On the seventh day, the cell supernatant was collected for screening.
[0052] The screening process is divided into two steps: the first step is to screen the positive cell wells using the IC-ELISA method, and the second step is to use famoxadone as a standard and measure the inhibitory effect of the positive cells using the IC-ELISA method;
[0053] The cell wells with good inhibition to the oxadiazonone standard were selected and subcloned using the limiting dilution method. Seven days later, the cells were tested using the same method.
[0054] Subcloning was performed three times according to the above method, and finally the famoxadone monoclonal antibody cell line SFA was obtained.
[0055] Example 5 Preparation and identification of famoxadone monoclonal antibodies
[0056] 8-10 week old BALB / c mice were injected intraperitoneally with 1 mL of sterile paraffin oil. Seven days later, 1×10 6 From the seventh day, the ascites of the oxadiazonone hybridoma cells were collected and the antibodies were purified by the caprylic acid-saturated ammonium sulfate method.
[0057] Under slightly acidic conditions, octanoic acid can precipitate other miscellaneous proteins in the ascites except IgG immunoglobulin, and then centrifuge and discard the precipitate; then use an equal amount of saturated ammonium sulfate solution to precipitate IgG type monoclonal antibodies, centrifuge, discard the supernatant, dissolve it with 0.01M PBS solution (pH 7.4), dialyze and desalt, and finally obtain the purified monoclonal antibody and store it at -20°C.
[0058] The IC of the monoclonal antibody against famoxadone was determined using an indirect competitive ELISA. 50 The value is 1.31 ng / mL, and the cross-over rate to oxadiazolone analogs is less than 1%, indicating that it has good sensitivity to oxadiazolone and can be used for oxadiazolone immunoassay detection (cross-over rate = (IC 50 / analog IC 50 )×100%).
[0059] The IC values of the above monoclonal antibodies for analogs such as oxazolidinone, oxazolidinone, and fenamidone were verified. 50 The cross-reaction rates are shown in the table below.
[0060] Table 1 IC values of famoxadone monoclonal antibodies against oxadone, oxadone and fenamidone 50 and cross-reaction rate
[0061] Example 6 Application of famoxadone monoclonal antibody
[0062] The monoclonal antibody prepared from the hybridoma cell line in vivo via ascites was applied to the ELISA spike-recovery test of famoxadone. The specific steps are as follows:
[0063] (1) Coat a 96-well microtiter plate with 100 μL of the coating agent diluted in carbonate buffer (CBS) at a concentration of 0.3 μg / mL per well. Incubate at 37°C for 2 h. Wash the plate three times with PBST solution, 200 μL per well each time for 3 min each time, and pat dry.
[0064] (2) Block with CBS containing 0.2% gelatin, 200 μL per well, at 37°C for 2 h, wash the plate three times with PBST, 200 μL per well each time, for 3 min each time, and pat dry;
[0065] (3) Prepare 0, 0.04, 0.12, 0.37, 1.11, 3.33, 10 and 30 ng / mL of famoxadone standard solutions using phosphate buffered saline (PBS). Add the standard solutions and the sample extracts to the blocked ELISA plate, 50 μL per well. Repeat for 3 wells for each sample. Then add 50 μL of anti-famoxadone monoclonal antibody diluted 1:32000 to each well. Incubate at 37°C for 0.5 h, then wash the plate and pat dry.
[0066] (4) Add 100 μL of HRP-labeled goat anti-mouse IgG secondary antibody diluted 1:3000 in PBS containing 0.1% gelatin to each well, react at 37°C for 0.5 h, and then wash the plate and pat dry.
[0067] (5) Add 100 μL of TMB colorimetric solution to each well. After color development at 37°C for 15 min, add 50 μL of 2 M H2SO4 stop solution to each well and measure the absorbance at 450 nm.
[0068] The standard curve of the inhibition of famoxadone monoclonal antibody to famoxadone is shown in Figure 1. The IC of famoxadone monoclonal antibody was determined by IC-ELISA. 50 The value was 1.31 ng / mL, indicating that the antibody had good sensitivity to famoxadone and could be used for immunoassay detection of famoxadone.
[0069] Obviously, the above embodiments are merely examples for clarity of explanation and are not intended to limit the implementation methods. Those skilled in the art will appreciate that other variations or modifications can be made based on the above description. It is not necessary and impossible to enumerate all implementation methods here. Obvious variations or modifications arising therefrom remain within the scope of protection of the present invention.
Claims
1. A hybridoma cell line secreting a monoclonal antibody against famoxadone, characterized in that: The hybridoma cell line was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on February 8, 2023, with the deposit number CGMCC No.45462.
2. The hybridoma cell line according to claim 1, characterized in that The hybridoma cell line is obtained by immunizing an animal with a complete antigen prepared with the oxadiazine hapten shown in the following structure:
3. The hybridoma cell line according to claim 2, characterized in that: The complete antigen is obtained by coupling the oxadiazonone hapten with a carrier protein.
4. The hybridoma cell line according to claim 3, characterized in that: The carrier protein is bovine serum albumin or ovalbumin.
5. Use of the hybridoma cell line according to any one of claims 1 to 4 in the detection of famoxadone.
6. A monoclonal antibody against famoxadone, characterized in that: The famoxadone monoclonal antibody is secreted by the hybridoma cell line according to any one of claims 1 to 4.
7. Use of the famoxadone monoclonal antibody according to claim 6 in detecting famoxadone.
8. A product for detecting oxathiapiprolin, characterized in that: The famoxadone detection product comprises the famoxadone monoclonal antibody according to claim 6.
9. The famoxadone detection product according to claim 8, characterized in that: The oxathiapiprolin detection product also includes an oxathiapiprolin coating source.
10. Use of the famoxadone detection product according to claim 8 or 9 in food safety detection.
Citation Information
Patent Citations
Kit for detecting food safety by chemiluminescence and preparation method of kit
CN107991480A
Hybridoma cell strain capable of secreting isoxaflutole monoclonal antibody and application of hybridoma cell strain
CN112574957A
Hybridoma cell strain secreting famoxadone monoclonal antibody and application thereof
CN116376847A
Cited By
Hybridoma cell strain and antibody for detecting rituximab and biosimilar drugs thereof and application of hybridoma cell strain and antibody
CN119570743A
Hybridoma cell strain secreting napropamide monoclonal antibody and application of hybridoma cell strain
CN119979475A
